Racial and ethnic minorities that are underrepresented in medicine have even lower representation in leadership of NCI-designated cancer centers, a study by Memorial Sloan Kettering Cancer Center researchers found.
This is the first installment of conversations about diversity, equity, and inclusion in recruitment and mentorship at academic cancer centers.
Pride month is upon us, and the rainbow flag is flying high. At levels that would have been unimaginable a few decades ago, corporate sponsors acknowledge and celebrate the right of LGBTQ+ individuals to live free of violence, discrimination, and oppression.
We’ve all heard this story before, just with a different set of names and places. Man harasses woman after woman, eventually someone (usually a woman) is brave enough to report him, a quiet investigation confirms the reports, and he quietly and seamlessly gets hired elsewhere with no one the wiser.
The FDA Oncologic Drugs Advisory Committee, in an 13-4 vote, recommended against approval of retifanlimab, a PD-1 inhibitor, for the treatment of squamous carcinoma of the anal canal.
The NCI Board of Scientific Advisors approved four new concepts, which includes Requests for Applications, Cooperative Agreements, and Program Announcements.
An NCI press conference is rarely a tabloid affair—except on Sept. 30, 1974. What was anticipated to be a dry occasion shifted when Betty Ford, wife of President Gerald Ford, underwent a radical mastectomy Sept. 28.
John H. Stewart was named center director of the LSU Health New Orleans/LCMC Health Cancer Center.
Julio Aguirre-Ghiso was named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program at Albert Einstein Cancer Center.
Lauren Hackett was named deputy director of administration of Albert Einstein Cancer Center and associate vice president of cancer medicine at Montefiore Medicine.
